NCT06034860 - Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Non Small Cell Lung CancerHepatocellular CarcinomaMelanomaRenal Cell CarcinomaMicrosatellite Instability HighMismatch Repair DeficiencyMesotheliomaEsophageal Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaCervical Cancer

Interventions

DRUG

MT-8421

Experimental treatment with MT-8421

DRUG

Nivolumab

480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts

Trial Locations (5)

10065

Weill Cornell Medicine, New York

22031

NEXT Oncology, Fairfax

47905

Horizon Oncology Research, LLC, Lafayette

63110

Washington University in St. Louis, St Louis

90025

The Angeles Clinic, Los Angeles